89bio Inc., of San Francisco, priced its public offering of about 2.6 million shares at $27.50 per share, grossing the company approximately $72.9 million. The underwriters have a 30-day option to purchase an additional 397,440 shares. BofA Securities, SVB Leerink and RBC Capital Markets are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as co-manager for the offering, which is scheduled to close on July 10. Shares of 89bio (NASDAQ:ETNB) closed down $2.09, or 6.3%, to $30.96 on July 8.

Acceleron Pharma Inc., of Cambridge, Mass., closed its public offering of about 5.6 million shares, including the full exercise of the underwriters’ option to purchase additional shares, at $92.50 per share, grossing the company approximately $492.5 million. J.P. Morgan, SVB Leerink and Cowen acted as joint bookrunners for the offering. Barclays, Credit Suisse and Piper Sandler & Co. also acted as joint book-running managers. H.C. Wainwright & Co. acted as lead manager.

Aeterna Zentaris Inc., of Charleston, S.C., closed its public offering of about 17.5 million units at 45 cents per unit and 9.1 million prefunded units at a price to the public of $0.4499 per pre-funded unit. Each unit consists of a share and a warrant to purchase an additional share. The offering will gross the company approximately $12 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Akero Therapeutics Inc., of South San Francisco, priced its public offering of about 5.2 million shares at $36 per share, grossing the company $188.2 million. The underwriters have a 30-day option to purchase up to an additional 784,224 shares. J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group LLC. are acting as joint book-running managers for the offering, which is scheduled to close on July 10. Shares of Akero (NASDAQ:AKRO) closed up $2.10, or 5.7%, to $39.16 on July 8.

Ascendis Pharma A/S, of Copenhagen, Denmark, priced its public offering of about 4.2 million American depositary shares (ADSs) for $142 per ADS, grossing the company approximately $569.2 million. The underwriters have a 30-day option to purchase up to an additional 633,802 ADSs. The company plans to use the proceeds for clinical development, regulatory approval and commercial preparations for Transcon hGH, to fund clinical development of Transcon PTH and Transcon CNP, to identify and progress development of new product candidates and for working capital and general corporate purposes. J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Credit Suisse Securities LLC, Cantor Fitzgerald & Co. and Canaccord Genuity LLC are acting as co-lead managers for the offering, and Oppenheimer & Co. Inc., Wedbush Securities Inc. and Kempen & Co. are acting as co-managers for the offering, which is scheduled to close on July 10. Shares of Ascendis (NASDAQ:ASND) closed down $2.33, or 1.6%, to $145.27 on July 8.

Therapeutics Acquisition Corp., of Boston, priced its IPO of 11.8 million shares at $10 per share, grossing the company $118 million. Therapeutics Acquisition is a blank check company sponsored by RA Capital Management LP, which was formed with a plan to combine with one or more businesses in the health care industry. The underwriter has a 45-day option to purchase up to an additional 1.8 million shares. Shares of Therapeutics Acquisition (NASDAQ:TXAC) closed at $12.24 on its first day of trading.

Vir Biotechnology Inc., of San Francisco, priced its public offering of about 7.1 million shares at $42 per share, grossing the company approximately $300 million. The underwriters have a 30-day option to purchase up to about 1.1 million additional shares. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Barclays are acting as joint book-running managers for the offering. Needham & Co. is acting as lead manager for the offering, which is scheduled to close on July 10. Shares of Vir (NASDAQ:VIR) closed up $1.72, or 3.9%, to $46.07 on July 8.

No Comments